Why the study?
The optimal timing for initiating P2Y12 inhibitor therapy in patients undergoing PCI remains controversial.
Does DAPT pretreatment reduce in-hospital stent thrombosis and improve clinical outcomes in patients with CCS and NSTEMI undergoing PCI?
Population
44412 patients (53898 PCI procedures) with CCS and NSTEMI in the France PCI registry
Comparison
DAPT pretreatment vs no pretreatment
Design
Registry-based cohort study
Follow-up
One year
Key result
DAPT pretreatment in patients undergoing PCI for CCS and NSTEMI was associated with a significantly lower incidence of in-hospital stent thrombosis (0.1% vs. 0.4%; OR 0.35, 95% CI 0.22-0.57).
Authors
Loading...
Supports DAPT pretreatment to reduce stent thrombosis in PCI; extends observational data but leaves open need for RCTs.
Cohort (n=44,412)
Yes
Does DAPT pretreatment reduce in-hospital stent thrombosis and improve clinical outcomes in patients with CCS and NSTEMI undergoing PCI?
Effect estimate: OR 0.35 (95% CI 0.22 to 0.57)
Absolute Event Rate: 0.1% vs 0.4%
In a large real-world registry of patients undergoing PCI for CCS or NSTEMI, DAPT pretreatment significantly reduced in-hospital stent thrombosis and 1-year mortality without increasing major bleeding risk.
Rangé et al. (2025) conducted a cohort in CCS and NSTEMI treated by PCI (n=44,412). Dual antiplatelet therapy (DAPT) pretreatment vs. No pretreatment was evaluated on Incidence of in-hospital definite stent thrombosis (OR 0.35, 95% CI 0.22 to 0.57). DAPT pretreatment in patients undergoing PCI for CCS and NSTEMI was associated with a significantly lower incidence of in-hospital stent thrombosis (0.1% vs. 0.4%; OR 0.35, 95% CI 0.22-0.57).